Pfizer Oncology Pipeline Takes Hit With Dacomitinib Lung Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Expectations for the asset hadn’t been high, but failure of two Phase III lung cancer studies of the irreversible pan-HER inhibitor dacomitinib may remove a potential competitor for Boehringer Ingelheim’s recently approved irreversible EGFR inhibitor Gilotrif.